Company Northwest Biotherapeutics, Inc Nasdaq
Equities
US66737P6007
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Immunotherapies for Cancer
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +14.80% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States, Germany, United Kingdom and Netherlands
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +14.80% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Linda F. Powers
CEO | Chief Executive Officer | 68 | 07-05-16 |
Alton L. Boynton
FOU | Founder | 79 | 96-03-17 |
Marnix L. Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 99-12-31 |
David Innes
IRC | Investor Relations Contact | - | 19-02-25 |
General Counsel | 78 | 11-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alton L. Boynton
FOU | Founder | 79 | 96-03-17 |
Linda F. Powers
CEO | Chief Executive Officer | 68 | 07-05-16 |
Navid Malik
BRD | Director/Board Member | 55 | 12-03-31 |
Director/Board Member | 74 | 16-01-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,200,000 | 0 | 0 | 89.76 % |
Stock B | 1 | 1,208,177,416 | 1,084,468,382 ( 89.76 %) | 0 |
Company contact information
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane Suite 800
20814, Bethesda
+240 497 9024
http://www.nwbio.comSector
1st Jan change | Capi. | |
---|---|---|
+3.95% | 111B | |
+11.45% | 105B | |
-12.55% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.67% | 16.96B | |
+3.11% | 13.7B | |
+37.02% | 12.45B |